Genome-wide association and candidate gene studies implicate different genetic variants within the 6p21 chromosomal region with different non-Hodgkin lymphoma (NHL) subtypes. Complementing these efforts, we conducted human leukocyte antigen (HLA) class I and class II genotyping among 610 NHL cases and 555 controls of non-Hispanic white descent from a US multicenter study. Allele-disease associa...

INTRODUCTION Non-Hodgkin's lymphomas (NHL) in China appear to have many characteristics different from those Western countries, but clinical studies to provide details have been rare so far. METHODS This study retrospectively analyzed the characteristics of clinical and pathological data for the 1248 NHL patients in the Shandong region of China between 2002 and 2010. RESULTS From 2002 to 20...

ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). Bcl-2 is a key protein that inhibits the intrinsic mitochondrial pathway of apoptosis. First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, ...

BACKGROUND Non-Hodgkin lymphoma (NHL) comprises distinct tumor subtypes. Although mortality from NHL overall has changed dramatically in the United States over time, little is known about trends for subtypes, because death certificates do not record this information. METHODS Using data from U.S. Surveillance, Epidemiology, and End Results (SEER) areas, we assessed NHL mortality rates and mapp...

Patients with autoimmune disorders seem to have an elevated risk of lymphoma, especially non-Hodgkin's lymphoma (NHL). The increased risk has been attributed to the disturbance of immune function found in these patients or to the immunosuppressive therapy used to treat the autoimmune disorders. However, little information exists about the estimated baseline risk for lymphoma in patients with pr...

Vol. 31 No. 5 • May 2006 • P&T® 273 INTRODUCTION Non-Hodgkin’s lymphoma (NHL) is the most common cancer of the lymphatic system. Since the early 1970s, the incidence of NHL has nearly doubled. Overall, the five-year survival rate is 59%. Of the nearly 500,000 Americans with lymphoma, approximately 332,000 have NHL. Each year, more than 56,390 new cases of NHL are diagnosed and 19,200 Americans ...

Two patients developed non-Hodgkin's lymphoma (NHL) six and ten years after radiotherapy and chemotherapy for Hodgkin's disease nodular sclerosis type. The histological classification of the developing NHL for the two patients was: IgG (K) secreting lymphoplasmacytoid lymphoma of the stomach, and immunoblastic lymphoma of the cervical lymph nodes. Both patients responded well to conventional ch...

BACKGROUND AND OBJECTIVES The prognosis in patients with primary refractory or relapsed high grade non-Hodgkin's lymphoma (NHL) is very poor--the 5-year survival being generally reported at 10%. DESIGN AND METHODS Multiple salvage regimens have been investigated and, while response rates of 50-80% have been noted in selected patients, the long-term prognosis remains poor. Following the encour...

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of B cell non-Hodgkin's lymphoma (NHL), encompassing 30-40% of the estimated 70,000 cases of NHL in 2014 in the USA. Despite major improvements with immune-chemotherapy, the fraction of patients who still succumb to a refractory or relapsed disease remains high. This review addresses whether the better understanding of the biology...

Introduction: Interleukin-1 receptor-associated kinase 4 (IRAK4) is essential for toll-like receptor (TLR) and interleukin-1 (IL-1R) signaling in immune cells including B lymphocytes. It forms the Myddosome complex with myeloid differentiation primary response 88 (MYD88) adaptor protein, driving maximal activation of Nuclear Factor Kappa (NFkB) causing inflammatory responses tumor promotion. Pr...